Related Experiment Video
Updated: May 21, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Transabdominal intestinal ultrasound parameters as intermediate treatment targets in a treat-to-target strategy for
Longxi Yun1, Zhaojue Wang2, Qingli Zhu2
1Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background/Aims:
This study aimed to investigate the prognostic value of early post-induction intestinal ultrasound (IUS) findings in predicting long-term clinical outcomes among patients with moderate-to-severe ulcerative colitis (UC).
Methods:
This retrospective, single-center study consecutively enrolled patients with moderate-to-severe, left-sided or extensive UC. Clinical endpoints were assessed at the end of follow-up or 1 year after induction therapy (for patients with at least 1 year of follow-up) and categorized as clinical remission (Short Clinical Colitis Activity Index [SCCAI] ≤ 2) or non-remission (SCCAI > 2). Patients who experienced a negative disease course before the evaluation point were classified as clinical non-remission.
Results:
A total of 56 patients were included. The bowel wall thickness (BWT; 5.1 ± 1.7 mm vs. 6.0 ±1.4 mm; P= 0.032) and Milan ultrasound criteria (MUC; 8.3 ± 3.2 vs. 9.9 ± 2.2; P= 0.029) evaluated at early follow-up IUS were lower for patients reaching longterm clinical remission. Patients with BWT < 5 mm on early follow-up IUS (83% vs. 45%; P= 0.006) or MUC < 6.2 (100% vs. 45%; P< 0.001) had a significantly higher rate of long-term clinical remission. Kaplan-Meier analysis revealed a lower cumulative probability of a negative disease course in patients with BWT < 5 mm (P= 0.025) or MUC < 6.2 (P= 0.025). Cox regression analysis identified BWT ≥ 5 mm as an independent predictor of a negative disease course.
Conclusions:
BWT <5 mm and MUC < 6.2 may serve as intermediate targets for IUS-guided "treat-to-target" strategy, offering a practical approach to improve longterm clinical remission in patients with moderate-to-severe UC.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
